MiniMed Group heads into its September 1 earnings release with one notable shift since the last note: the lending market has partially loosened, even as options traders remain unusually defensive.
The most meaningful change from yesterday is in borrow availability. After touching a 52-week floor of 14.2% on August 21 and tightening back to 18.7% on August 26, availability has now rebounded to 53.8% — meaning roughly one share is available for every two already borrowed. Cost to borrow has also eased from the 6.1% peak two days ago back to 3.98%, still nearly four times the level seen in mid-August. The short position itself has drifted slightly higher on the day, up about 2.8% to 6.72 million shares, though it remains roughly 9% lighter than a week ago. The overall short-covering trend flagged in previous notes is intact; borrow conditions have just become fractionally less punishing for those who held their positions through the tightest days.
Options defensiveness, however, has not softened. The put/call ratio is 2.79 — almost identical to August 27's reading and still running nearly two standard deviations above its 20-day average of 1.96. That elevated put demand has been sticky across the past week, suggesting hedging activity is driven by the earnings event itself rather than by borrow tightness. The stock has gained 3% on the day to $20.10, and is up roughly 14% over the past month, so the hedging comes against a backdrop of genuine price appreciation rather than distress.
The analyst setup offers a mixed signal worth noting. UBS assumed coverage in late July with a Buy and a $25 target — the most recent bellwether action in the data. Wells Fargo and BofA both hold positive ratings but trimmed targets in May and June, to $22 and $20 respectively, after the prior earnings print. The consensus mean target is $20.83, barely above the current price. Bulls point to MiniMed's leadership in diabetes technology and a strong patent position; bears flag the low market penetration rate and near-term margin pressure from product launches. The history is also relevant: the June 3 print produced a one-day gain of more than 14% and a five-day move of nearly 20%, while the April event resulted in a modest decline. Two prints, two very different outcomes.
The September 1 report will test whether the recent price rally — and the insider selling by the CEO and CFO in late July at prices well below current levels — reflects a market ahead of the company, or a company about to justify the move.
See the live data behind this article on ORTEX.
Open MMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
